Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 6, 2010, Pages 2033-2037

  Choi, Soo Jeong ^a   Moon, Myoung Ju ^a   Lee, So Deok ^a   Choi, Sang Un ^b   Han, Sun Young ^b   Kim, Yong Chul ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Acute myeloid leukemic cells; Cell cycle; FLT3 kinase; Indirubin

Indexed keywords

ENZYME INHIBITOR; FMS LIKE RECEPTOR TYROSINE KINASE 3; INDIRUBIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MUTATION; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE;

EID: 77549087807     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.039     Document Type: Article

References (23)

1. Rosnet O., Buhring H.J., DeLapeyriere O., Beslu N., Lavagna C., Marchetto S., Rappold I., Drexler H.G., Birg F., Rottapel R., Hannum C., Dubreuil P., and Birnbaum D. Acta Haematol. 95 (1996) 218-223
2. Gilliland D.G., and Griffin J.D. Curr. Opin. Hematol. 9 (2002) 274-281
3. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., and Misawa S. Leukemia 10 (1996) 1911-1918
4. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa T., Okuda T., Sonoda Y., Abe T., Kahsima K., Matsuo Y., and Naoe T. Leukemia 11 (1997) 1605-1609
5. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., Akiyama H., Saito K., Nishimura M., Motoji T., Shinagawa K., Takeshita A., Saito H., Ueda R., Ohno R., and Naoe T. Blood 97 (2001) 2434-2439
6. Kottaridis P.D., Gale R.E., and Linch D.C. Br. J. Haematol. 122 (2003) 523-538
7. Chen W., Jones D., Jeffrey Medeiros L., Luthra R., and Lin P. Br. J. Haematol. 130 (2005) 726-728
8. Levis M., and Small D. Leukemia 17 (2003) 1738-1752
9. Ozeki K., Kiyoi H., Hirose Y., Iwai M., Ninomiya M., Kodera Y., Miyawaki S., Kuriyama K., Shimazaki C., Akiyama H., Nishimura M., Motoji T., Shinagawa K., Takeshita A., Ueda R., Ohno R., Emi N., and Naoe T. Blood 103 (2004) 1901-1908
10. Advani A.S. Curr. Pharm. Des. 11 (2005) 3449-3457
11. Paz K., and Zhu Z. Expert Opin. Ther. Targets 9 (2005) 1147-1163
12. Pandey A., Volkots D.L., Seroogy J.M., Rose J.W., Yu J.C., Lambing J.L., Hutchaleelaha A., Hollenbach S.J., Abe K., Giese N.A., and Scarborough R.M. J. Med. Chem. 45 (2002) 3772-3793
13. Dai Y., Hartandi K., Ji Z., Ahmed A.A., Albert D.H., Bauch J.L., Bouska J.J., Bousquet P.F., Cunha G.A., Glaser K.B., Harris C.M., Hickman D., Guo J., Li J., Marcotte P.A., Marsh K.C., Moskey M.D., Martin R.L., Olson A.M., Osterling D.J., Pease L.J., Soni N.B., Stewart K.D., Stoll V.S., Tapang P., Reuter D.R., Davidsen S.K., and Michaelides M.R. J. Med. Chem. 50 (2007) 1584-1597
14. Moon M.J., Lee S.K., Lee J.W., Song W.K., Kim S.W., Kim J.I., Cho C., Choi S.J., and Kim Y.C. Bioorg. Med. Chem. 14 (2006) 237-246
15. Zhou J., Bi C., Janakakumara J.V., Liu S.C., Chng W.J., Tay K.G., Poon L.F., Xie Z., Palaniyandi S., Yu H., Glaser K.B., Albert D.H., Davidsen S.K., and Chen C.S. Blood 113 (2009) 4052-4062
16. 50 was calculated by nonlinear regression using Prism version 5.01 (GraphPad).
17. 50 was calculated by nonlinear regression using Origin version 7.5.
18. Yee K.W.H., O'Farrell A.M., Smolich B.D., Cherrington J.M., McMahon G., Wait C.L., McGreevey L.S., Griffith D.J., and Heinrich M.C. Blood 100 (2002) 2941-2949
19. Tallman M.S., Gilliland D.G., and Rowe J.M. Blood 106 (2005) 1154-1163
20. Mollgard L., Deneberg S., Nahi H., Bengtzen S., Jonsson-Videsater K., Fioretos T., Andersson A., Paul C., and Lehmann S. Cancer Chemother. Pharmacol. 62 (2008) 439-448
21. Levis M., Pham R., Smith B.D., and Small D. Blood 104 (2004) 1145-1150
22. Knapper S., Mills K.I., Gilkes A.F., Austin S.J., Walsh V., and Burnett A.K. Blood 108 (2006) 3494
23. Cell cycle analysis protocol. MV4;11 cell were grown in 24-well plates (500,000 cells per well) and treated with compounds for 48 h. Cells were then fixed and stained with propidium iodide (Sigma) and subjected to flow cytometry using FACSCalibur™ (BD Biosciences). Data were analyzed by CellQuest Pro (BD Biosciences).